Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | ERN1 | O75460 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.39 |
| ▸ | IKBKB | O14920 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.36 |
| ▸ | MAT2A | P31153 | 1/20 | 0.36 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.36 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31227003 | 1.00 | ACHE (0.48) | ACHEALDH1A1TSHRERN1MEN1 | |
| SCHEMBL95708 | 0.83 | ERN1 (0.50) | ALDH1A1ERN1MEN1KMT2ATDP1 | |
| SCHEMBL66979 | 0.83 | ALDH1A1 (0.52) | ACHEALDH1A1TSHRMEN1KMT2A | |
| SCHEMBL28641344 | 0.80 | ALDH1A1 (0.50) | ACHEALDH1A1TSHRMEN1KMT2A | |
| SCHEMBL3271795 | 0.78 | ERN1 (0.40) | ACHEALDH1A1TSHRERN1MEN1 | |
| SCHEMBL12091400 | 0.77 | ACHE (0.48) | ACHEALDH1A1TSHRTDP1NFE2L2 | |
| SCHEMBL2562309 | 0.77 | PDE7A (0.43) | ALDH1A1TSHRMEN1KMT2ATRIM24 | |
| SCHEMBL12656511 | 0.76 | ACHE (0.46) | ACHETDP1NFE2L2KCNH2MAT2A | |
| SCHEMBL652253 | 0.74 | ERN1 (0.59) | ALDH1A1TSHRERN1MEN1KMT2A | |
| SCHEMBL17027637 | 0.74 | ALDH1A1 (0.44) | ACHEALDH1A1TSHRERN1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 156 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114409595-A | 1-styryl isoquinoline derivative and preparation and application thereof | 南华大学附属第一医院 | 2022-04-29 | — | — | CN | claimed |
| EP-4713096-A1 | CDK INHIBITOR COMPOUNDS | Aleksia Therapeutics, Inc. (US) | 2026-03-25 | — | — | EP | disclosed |
| US-20250326744-A1 | PIPERAZINE DERIVATIVE OR SALT THEREOF, AND PHARMACEUTICAL COMPOSITION | FUJIFILM CORPORATION (JP) | 2025-10-23 | — | — | US | disclosed |
| EP-4587014-A2 | C5AR1 ANTAGONISTS AND USES THEREOF | Vanqua Bio, Inc. (US) | 2025-07-23 | — | — | EP | disclosed |
| US-12281057-B2 | Carboxamides as modulators of sodium channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-04-22 | — | — | US | disclosed |
| CN-119816484-A | Novel piperazine derivative or salt thereof and pharmaceutical composition | 富士胶片株式会社 | 2025-04-11 | — | — | CN | disclosed |
| US-20250115608-A1 | HORMONE RECEPTOR MODULATORS FOR TREATING METABOLIC CONDITIONS AND DISORDERS | ARDELYX, INC. (US) | 2025-04-10 | — | — | US | disclosed |
| US-12209088-B2 | Hormone receptor modulators for treating metabolic conditions and disorders | ARDELYX, INC. (US) | 2025-01-28 | — | — | US | disclosed |
| WO-2024238574-A1 | CDK INHIBITOR COMPOUNDS | ALEKSIA THERAPEUTICS, INC. (US) | 2024-11-21 | — | — | WO | disclosed |
| EP-3651752-B1 | CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELS | VERTEX PHARMA (US) | 2024-11-20 | — | — | EP | disclosed |
| US-7674828-B2 | Urea antagonists of P2Y1receptor useful in the treatment of thrombotic conditions | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-03-09 | — | — | US | disclosed |
| US-20090286800-A1 | Glucokinase Activators | TAKEDA SAN DIEGO, INC. (US) | 2009-11-19 | — | — | US | disclosed |
| US-20080280905-A1 | UREA ANTAGONISTS OF P2Y1 RECEPTOR USEFUL IN THE TREATMENT OF THROMBOTIC CONDITIONS | BRISTOL MYERS SQUIBB COMPANY (US) | 2008-11-13 | — | — | US | disclosed |
| US-20070219216-A1 | 1-Alkylpiperazinyl-Pyrrolidin-2,5-Dione Derivatives as Adrenergic Receptor Antagonists | RANBAXY LABORATORIES LIMITED (IN) | 2007-09-20 | — | — | US | disclosed |
| US-5340833-A | Antiarthritic, antiinflammatory, antitumor agents | EISAI CO., LTD. (JP) | 1994-08-23 | — | — | US | disclosed |
| EP-0568289-A2 | Benzothiophenes and thienothiophenes and related compounds useful, for example, as urokinase inhibitors | Eisai Co., Ltd. (JP) | 1993-11-03 | — | — | EP | disclosed |
| US-4224340-A | Anti-inflammatory compositions containing α-phenyl-N-phenylnitrone compounds | WILLIAM H. RORER, INC. (US) | 1980-09-23 | — | — | US | disclosed |
| US-4214003-A | ANTIINFLAMMATORY AGENTS | WILLIAM H. RORER, INC. (US) | 1980-07-22 | — | — | US | disclosed |
| US-4197314-A | WITH A DIPHENYL NITRONE | WILLIAM H. RORER, INC. (US) | 1980-04-08 | — | — | US | disclosed |
| US-4153722-A | ANTIINFLAMMATORY, A-PHENYL-N-PHENYLNITRONE | WILLIAM H. RORER, INC. (US) | 1979-05-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080280905-A1 | UREA ANTAGONISTS OF P2Y1 RECEPTOR USEFUL IN THE TREATMENT OF THROMBOTIC CONDITIONS | P2RY1, P2RY11, P2RY2 | ACHE 3689/4885ALDH1A1 1978/4885TSHR 1134/4885 |
| US-20070219216-A1 | 1-Alkylpiperazinyl-Pyrrolidin-2,5-Dione Derivatives as Adrenergic Receptor Antagonists | ADRA1D, ADRA1A, ADRB1 | ACHE 1897/4885ALDH1A1 51/4885TSHR 408/4885 |
| US-12209088-B2 | Hormone receptor modulators for treating metabolic conditions and disorders | NR1H4, FXR1, GLP1R | ACHE 4766/4885ALDH1A1 2057/4885TSHR 19/4885 |
| US-20090286800-A1 | Glucokinase Activators | GCK, GCKR, GALK1 | ACHE 898/4885ALDH1A1 1149/4885TSHR 3402/4885 |
| US-20250326744-A1 | PIPERAZINE DERIVATIVE OR SALT THEREOF, AND PHARMACEUTICAL COMPOSITION | ABCB11, ABCC1, SLC11A2 | ACHE 2892/4885ALDH1A1 774/4885TSHR 3952/4885 |
| US-20250115608-A1 | HORMONE RECEPTOR MODULATORS FOR TREATING METABOLIC CONDITIONS AND DISORDERS | NR1H4, FXR1, GLP1R | ACHE 4766/4885ALDH1A1 2057/4885TSHR 19/4885 |
| US-12281057-B2 | Carboxamides as modulators of sodium channels | TRPV1, SCN2A, SCN10A | ACHE 514/4885ALDH1A1 2665/4885TSHR 3163/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.